Local Institution

Tulsa, Oklahoma 74136

0 studies enrolling now · 16 studies all time

What they study most

Alzheimer's Disease, Breast Cancer, Chronic Myeloid Leukemia, Dementia, Diabetes Mellitus, Diabetes Mellitus II, Diabetes Mellitus, Type 2, Heart Disease, Hypertension, Ischemic Heart Disease, Leukemia, Leukemia, Lymphocytic, Acute, L2

Studies at this site

• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography — Stopped early
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone — Completed
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise — Completed
• Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis — Completed
• Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia — Completed
• PPAR - Combination With Metformin — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension — Completed
• Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone — Completed
• PPAR-COMBO With Sulfonylurea — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery — Completed
• A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early